{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:27:29Z","timestamp":1787164049667,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Monoclonal antibodies represent one of biomedicine's greatest successes, yet global access remains profoundly inequitable, with low- and middle-income countries bearing the brunt of limited access. This perspective proposes that long-acting infectious disease mAbs, starting with WHO-recommended nirsevimab for RSV prevention, could catalyze transformation by connecting with existing WHO Essential Medicines List mAbs. Picture two static half-circles: WHO Essential Medicines List mAbs with proven value but limited access, and infectious disease prevention mAbs with transformative potential. Connected, they form a complete wheel capable of rolling toward the aspirations of global pharmacoequity. HIV antiretroviral therapy demonstrates precedent\u2014costs declined 100-fold through political mobilization, not technological breakthroughs.<\/jats:p>","DOI":"10.3389\/fped.2026.1845146","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:18:34Z","timestamp":1782195514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Breaking the sound barrier: global monoclonal antibody pharmacoequity"],"prefix":"10.3389","volume":"14","author":[{"given":"Huub C.","family":"Gelderblom","sequence":"first","affiliation":[{"name":"Fred Hutch Cancer Center, Vaccine and Infectious Disease Division","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Gray","sequence":"additional","affiliation":[{"name":"South African Medical Research Council","place":["Cape Town, South Africa"]},{"name":"Infectious Disease and Oncology Research Institute, University of Witwatersrand","place":["Johannesburg, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kelley","sequence":"additional","affiliation":[{"name":"BK Biopharma Consulting, LLC","place":["Burlingame, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","year":"2026"},{"key":"B2","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2026.31.2.2500275","article-title":"Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian sentinel hospital network (FluCAN-PAEDS)","volume":"31","author":"Blyth","year":"2026","journal-title":"Euro Surveill"},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00431-026-06746-4","article-title":"Real-world impact of nirsevimab on the epidemiology and severity of pediatric respiratory syncytial virus infections: a three-season cohort study in Italy.","volume":"185","author":"Ferrari","year":"2026","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101597","DOI":"10.1016\/j.lanepe.2026.101597","article-title":"Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis.","volume":"63","author":"Perramon-Malavez","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-026-00348-z","article-title":"Estimation of public health impact with use of nirsevimab during the 2024-2025 RSV season in the USA: a modeling study","author":"Yarnoff","year":"2026","journal-title":"Pulm Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2200246","DOI":"10.1200\/GO.22.00246","article-title":"Cost-Effectiveness of the first line treatment options for metastatic renal cell carcinoma in India.","volume":"9","author":"Gupta","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e26257","DOI":"10.1002\/jia2.26257","article-title":"The potential of broadly neutralizing antibodies for HIV prevention.","volume":"27","author":"Gelderblom","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41590-024-01938-2","article-title":"Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.","volume":"25","author":"Wang","year":"2024","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.1002\/jia2.70077","article-title":"The HIV\/AIDS response as we knew it is over: where do we go from here?","volume":"29","author":"Beyrer","year":"2026","journal-title":"J Int AIDS Soc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2373330","DOI":"10.1080\/19420862.2024.2373330","article-title":"The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras.","volume":"16","author":"Kelley","year":"2024","journal-title":"MAbs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJMe2408591","article-title":"The real PURPOSE of PrEP - effectiveness, not efficacy.","volume":"391","author":"Walensky","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3018(24)00173-5","article-title":"The long wait for long-acting HIV prevention and treatment formulations.","volume":"11","author":"Venter","year":"2024","journal-title":"Lancet HIV"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1371\/journal.pmed.0030161","article-title":"How to take HIV antiretroviral medications on time without a watch in rural Uganda.","volume":"3","author":"Maier","year":"2006","journal-title":"PLoS Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jama.296.6.679","article-title":"Adherence to antiretroviral therapy in sub-saharan Africa and North America: a meta-analysis.","volume":"296","author":"Mills","year":"2006","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace.","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress.","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1093\/infdis\/jiaf216","article-title":"Polyclonal and monoclonal antibodies for the treatment and prevention of influenza.","volume":"232","author":"Beigel","year":"2025","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.lanmic.2024.07.010","article-title":"Antimicrobial resistance: a concise update.","volume":"6","author":"Ho","year":"2025","journal-title":"Lancet Microbe"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2502975122","DOI":"10.1073\/pnas.2502975122","article-title":"Operation warp speed offers a roadmap for improving the efficiency of bench to bedside medical advances.","volume":"122","author":"Corey","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","year":""},{"key":"B25","first-page":"193","article-title":"Who position paper on immunization to protect infants against respiratory syncytial virus disease, may 2025.","volume":"22","year":"2025","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1845146\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:18:35Z","timestamp":1782195515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1845146\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":25,"alternative-id":["10.3389\/fped.2026.1845146"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1845146","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1845146"}}